阿托伐他汀对非缺血性心力衰竭患者心功能及内皮舒张功能影响的研究  

Study of atorvastatin in patients with non-ischemic heart failure cardiac function and endothelial function

作　　者：胡慧[1] 高毅滨[1] 郑文武[1] 

机构地区：[1]泸州市人民医院心内科,四川泸州646000

出　　处：《西部医学》2011年第3期425-427,共3页Medical Journal of West China

基　　金：泸州市科研基金;泸市科函(2008-S-16)

摘　　要：目的探讨阿托伐他对非缺血性心力衰竭患者心功能及内皮舒张功能的影响。方法将60例扩张型心肌病(DCM)伴心力衰竭(HF)患者随机分为阿托伐他汀组、对照组各30例,分别于治疗前、治疗3、12个月检测NYHA分级、左室射血分数(LVEF)、血C反应蛋白(CRP)、血流介导的内皮依赖性血管舒张功能(FMD)、总胆固醇(TC)和低密度脂蛋白(LDL)。结果①在治疗3个月和12个月后阿托伐他汀组和对照组CRP、TC及LDL的水平均降低,EF、NYHA分级及FMD的水平均增加,但阿托伐他汀组优于对照组(P<0.05)。②阿托伐他汀组EF与CRP水平呈显著负相关(P<0.01),EF与FMD水平呈显著正相关(P<0.01),而EF与TC、LDL呈零相关;对照组EF与CRP、FMD、TC、LDL水平呈零相关。结论 DCM心力衰竭患者在常规治疗的基础上加用阿托伐他汀可显著改善左室功能及内皮舒张功能,其心功能的改善独立于降脂之外。Objective To study atorvastatin calcium（Ale） on the non-ischemic heart failure or dilated cardiomyopathy（DCM） patients with left ventricular ejection fraction（LVEF）,New York Heart Association（NYHA） cardiac function,serum C reactive protein（CRP）,flow-mediated endothelium-dependent vasodilation（FMD）,plasma total cholesterol（TC）,low density lipoprotein（LDL） of,for Ale treatment of DCM to provide more clinical basis.Methods 60 patients with DCM HF hospitalization were randomly divided into Ale group and control group.Ale group added Ale 10mg / d treatment of 12 months,respectively.NYHA classification,LVEF,CRP,FMD,TC and LDL were measured before and 3 months and 12 months after treatment.Results The patients in age,gender,disease duration,blood pressure,heart rate and the basic treatment routine was no significant difference（P0.05）.In the treatment of 3 months and 12 months,Atorvastatin group and control group CRP,TC,and LDL decreased and EF,NYHA classification and the average increased.In the atorvastatin group,CRP,TC and LDL levels reduced and the EF,NYHA classification increased in FMD levels higher than that in the control group（P0.05）.Atorvastatin group EF and CRP levels were significantly negatively correlated（r=-0.517,respectively,less than 0.01）,EF and FMD levels were significantly correlated（r=0.707,value less than 0.01）.Conclusion DCM heart failure patients based on conventional therapy plus atorvastatin 10mg/d treatment for 3 months and 12 months of treatment could significantly improve left ventricular function and endothelial function and reduce blood CRP,TC,LDL levels.Atorvastatin may improve cardiac function in patients with DCM by reducing CRP,improved endothelial function to achieve,independent of lipid-lowering beyond.

关 键 词：他汀类药物 非缺血性心力衰竭 心功能 CRP 内皮舒张功能 

分 类 号：R541.6[医药卫生—心血管疾病]